Market Overview

Juno Therapeutics Adds To Monday's Gain After Wedbush Upgrade

Related JUNO
9 Notable Biotechs Presenting At This Year's ASH Meeting
4 Biggest Technical Levels To Watch Friday Morning
Juno Clinical Trial Updates Continue To Impress (Seeking Alpha)

Juno Therapeutics Inc (NASDAQ: JUNO) shares are trading higher by $7.52, or 20 percent, at $44.00 in Tuesday's session. This comes on top of Monday's gain of $5.75, instigated by Gilead Sciences, Inc. (NASDAQ: GILD)'s take over of Kite Pharma Inc (NASDAQ: KITE) at a 30 percent premium to closing price Friday.

The catalyst for Tuesday's rally is an upgrade from Wedbush, who changed their rating from Neutral to Outperform.

After a flat open, it immediately found support just above Monday's closing price ($36.48), only reaching $36.50 before embarking on its major rally. The pace of the rally accelerated once it surpassed Monday's high ($37.50), so far reaching $44.32 as of 11:50 a.m. EST. That marks the highest level since it peaked on June 10, 2016, at $45.00.

Latest Ratings for JUNO

Nov 2017Leerink SwannMaintainsOutperform
Oct 2017Morgan StanleyMaintainsEqual-Weight
Sep 2017BarclaysInitiates Coverage OnOverweight

View More Analyst Ratings for JUNO
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Upgrades Technicals M&A Intraday Update


Related Articles (GILD + JUNO)

View Comments and Join the Discussion!

Partner Center